Bambusa Therapeutics SEC Filings
NASDAQ: BBTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
16.00+0.45 (+2.89%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Bambusa Therapeutics filing overview
This page lists 11 recent SEC filings by Bambusa Therapeutics (BBTX), including 5 4, 1 SCHEDULE 13D, 1 SCHEDULE 13G, 1 8-K. The latest current report (8-K), used to disclose material events such as earnings releases and executive changes, was filed on Nov 3, 2026. Form 10-K is the audited annual report, 10-Q the quarterly report, 8-K covers material events, and Form 4 reports insider transactions. All documents link directly to SEC EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
BBTX SEC filings
| Filed | Form | Description | Document |
|---|---|---|---|
| Nov 6, 2026 | SCHEDULE 13D | Beneficial ownership report (activist) | View on EDGAR |
| Nov 5, 2026 | SCHEDULE 13G | Beneficial ownership report (passive) | View on EDGAR |
| Nov 3, 2026 | 4 | Statement of changes in beneficial ownership | View on EDGAR |
| Nov 3, 2026 | 8-K | Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Regulation FD Disclosure | View on EDGAR |
| Nov 2, 2026 | 4 | Statement of changes in beneficial ownership | View on EDGAR |
| Nov 2, 2026 | 4 | Statement of changes in beneficial ownership | View on EDGAR |
| Nov 2, 2026 | 4 | Statement of changes in beneficial ownership | View on EDGAR |
| Nov 2, 2026 | 4 | Statement of changes in beneficial ownership | View on EDGAR |
| Oct 30, 2026 | 424B4 | Prospectus | View on EDGAR |
| Oct 26, 2026 | S-1/A | Registration statement (amendment) | View on EDGAR |
| Oct 9, 2026 | S-1 | Registration statement | View on EDGAR |